Recombinant Listeria promotes tumor rejection by remodeling tumor microenvironment dependent upon induction of functional CD8+ T cells

The scientific rationale for the clinical advancement of Lm-based immunotherapies is in part due to hallmark observations in the mouse infection model where a single immunization with sublethal doses of WT Lm confers lifelong protection against lethal WT Lm challenge. Protection is entirely dependent upon potent bacterial-specific CD4+ and CD8+ T cell immunity. While our previous investigations have demonstrated the antitumor potency of therapeutic immunization with LADD-Ag , here we describe for the first time, the immunologic correlates of this antitumor efficacy.